ALCAM and osteosarcoma: So, designing CARs targeting this cell surface molecule could be an effective anti-cancer immunotherapeutic strategy, as demonstrated by a pioneer study with human T cells engineered to express an anti-human CD166/ALCAM CAR (CD166.BBζ-CAR) against human osteosarcoma cell lines [59] (Figure 2A, right-hand side; Table 1).